title: Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
abstract: Several studies show that the antitumour activity of melphalan (MEL) and other alkylating agents can be enhanced by the selective inhibition of tumour blood flow, although the mechanism(s) underlying these interactions are unclear. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a new anticancer agent currently in phase I clinical trial, inhibits blood flow in murine tumours. DMXAA increased the activity of MEL against the MDAH-MCa-4 mouse mammary tumour maximally when MEL was given about 2 h after DMXAA, without compromising the maximal dose of the alkylating agent that could be given. The plasma pharmacokinetics of MEL were unchanged by DMXAA pretreatment, but the area under the concentration-time curve (AUC) for the tumour increased by 33% as a result of decreasing clearance (consistent with falling tumour blood flow). However, inhibition of tumour blood flow also leads to microenvironmental changes (e.g. acidosis and hypoxia) that might influence sensitivity to MEL. The sensitivity of KHT cells (freshly isolated from tumours) to MEL in vitro was increased by lowering of either pH or oxygen concentration (pO2), with an overall dose-modifying factor of 15 being recorded for aerobic cells at pH 7.4 versus hypoxic cells at pH 6.5. The cellular uptake of MEL by KHT cells was increased by 74% under hypoxia. Thus, DMXAA appears to augment the antitumour activity of MEL through two different mechanisms, increased exposure (via decreased tumour clearance of MEL) and increased sensitivity resulting from changes to the tumour microenvironment, both of which result from inhibition of tumour blood flow.
authors.affiliation: Department of Pathology, University of Auckland, New Zealand.
authors.forename: F B
authors.initials: FB
authors.lastname: Pruijn
authors.forename: M
authors.initials: M
authors.lastname: van Daalen
authors.forename: N H
authors.initials: NH
authors.lastname: Holford
authors.forename: W R
authors.initials: WR
authors.lastname: Wilson
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics / Q000494:pharmacology*; D015687:Cell Hypoxia; D004357:Drug Synergism; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000473:pathology; D008558:Melphalan / Q000493:pharmacokinetics / Q000494:pharmacology*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D014966:Xanthenes / Q000494:pharmacology*; D044004:Xanthones
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014966:Xanthenes; D044004:Xanthones; C066668:vadimezan; D008558:Melphalan